Pricing and Policies

AM 2026 CE recordings

Ethics in Motion: Navigating Connection and Change in Global Psychological Practice (3 hours) Presenters: Tomina J. Schwenke, PhD, ABPP, Emily Mouilso, PhD, and Amy Todey, PhD 

This engaging ethics workshop will use case studies on social media, global psychology, and interjurisdictional practice to examine emerging challenges in modern psychological work. Participants will review telepsychology and telemental health guidelines, ethical decision-making models, and frameworks for forensic work, mandated reporting, and social media practice. Diversity issues—including cultural contexts in high-conflict families, linguistic and disability concerns, and generational differences in technology use—will be integrated throughout. Using interactive methods such as open-ended questions, quizzes, and self-reflection, attendees will gain practical tools, decision trees, and greater capacity to ethically navigate evolving practice across state and international borders.

From Theory to Practice: Assessment and Treatment of Substance Use Disorder Using a Biopsychosocial Approach (3 hour)
Presenters: Kallio Hunnicutt-Ferguson, PhD, Samantha Patton, PhD, ABPP, and Martha Fiskeaux, PsyD

This introductory level workshop will explore the neurobiological, psychological, and social factors that contribute to substance use disorders (SUDs). We will discuss the ways in which stigma and bias affect individuals with SUDs, and how to approach assessment and treatment in a compassionate, nonjudgmental manner. We will review information on factors to assess when working with someone with an active SUD (e.g., even if not initially the focus of care). We will review the evidence base for treatments for SUDs as well as interventions for co-occurring disorders, and engage attendees in experiential practice of important assessment.

Mirror, mirror on the wall: Better body image for all (3 hours) Presenter: Sandra Wartski

Negative body image is curiously complex, quite common and clinically challenging. Beliefs about one’s body, including culturally-influenced idealizations about shape and size, are developed in multifactorial ways, and the unlearning of these beliefs is similarly multifaceted. This presentation will focus on the truths about body image, accompanied by a variety of multi-theoretical interventions to consider incorporating into therapeutic strategies related to body image improvement. Because research shows that anyone’s mental health would be improved with improved body image, all therapists would benefit from additional clinical skills that can assist in effectively navigating clients toward a life without critical body relationships.

MDMA combined with massed exposure therapy for PTSD (2 hours)

Presenters: Dr. Barbara Rothbaum & Dr. Jessica Maples-Keller

The pharmacotherapy and psychotherapy literatures for posttraumatic stress disorder (PTSD) will be succinctly reviewed and discussed, focusing on cognitive behavioral treatments (CBT), and the various CBT techniques will be briefly described, including virtual reality exposure therapy. Pharmacotherapy and combination pharmacotherapy and psychotherapy treatments for PTSD will be discussed. Innovations in the treatment of PTSD, including medium of delivery and novel combination treatment will be presented. An intensive outpatient treatment model and will be presented. In two phase 3 trials, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy, a non-directive therapeutic approach, resulted in significantly greater reductions in PTSD compared to placebo. The therapy model used in these trials has not previously been tested as a standalone therapy and is not an existing evidence based PTSD therapy. Prolonged Exposure (PE) is a gold standard PTSD intervention. Translational evidence indicates prolonged Exposure Therapy (PE) could represent the optimal psychotherapy to be combined with MDMA for PTSD intervention.
We have developed The METEMP Protocol for Massed Exposure Therapy Enhanced with MDMA for PTSD. We are piloting the combination of a two-week intensive PE protocol for treatment of PTSD with the addition of a 100 mg MDMA dose on Day 2, in which two imaginal exposure sessions are conducted during the MDMA session. Primary outcome is PTSD symptom reduction as assessed by independent raters via the Clinician-Administered PTSD Scale for DSM-5-Revised (CAPS-5-R) from pre-treatment compared to one month follow up. Currently 12 participants have been enrolled (N=12; 41.7% male; 41.7% civilian and 58.3% veteran). In preliminary analyses, CAPS-5-R decreased significantly from pre (M = 75.50, SD = 14.16) to 1 month (M = 16.48, SD = 20.89) (t = 12.33, df = 11, p < .001). MDMA enhanced massed exposure therapy for PTSD shows preliminary safety, feasibility, and efficacy, with a large decrease in CAPS-5 symptoms.